Dopamine receptor blockade (NMS) has a slow onset and typically evolves over several days after administration of a neuroleptic drug and responds to dopamine agonists such as bromocriptine.
receptor | LDL receptor | Receptor (biochemistry) | Continuous erythropoietin receptor activator | GABA receptor | Epidermal growth factor receptor | NMDA receptor | Sensory receptor | receptor (biochemistry) | metabotropic glutamate receptor | 5-HT2A receptor | VLDL receptor | TGF beta receptor 2 | receptor antagonist | epidermal growth factor receptor | Dopamine | dopamine | 5-HT receptor | RAR-related orphan receptor alpha | Metabotropic glutamate receptor 5 | Metabotropic glutamate receptor 2 | G protein-coupled receptor | AMPA receptor | Adenosine A1 receptor | Toll-like receptor | TNF receptor associated periodic syndrome | taste receptor | Sigma-1 receptor | Receptor antagonist | Receptor activity-modifying protein |
A-77636, a selective dopamine receptor D1 agonist